 |
What's New | ||
|
Faculty & Staff | ||
|
Joe B. Putnam, Jr., M.D. | ||
|
Education | ||
|
|||
|
Videos | ||
|
Research | ||
|
F.A.Q. | ||
|
Glossary of Terms | ||
|
Web Links | ||
|
Thoracic Center | ||
|
Contact Information | ||
Dr. Joe B. Putnam, Jr. was born in Franklin, North Carolina. In 1975, he attended the University of North Carolina at Chapel Hill, where he received his A.B. with honors in Chemistry and Zoology; remaining at the University of North Carolina, Dr. Putnam received his M.D., in 1979. Following that he completed his surgical internship and year as the Junior Assistant Resident in Surgery, at Johns Hopkins Hospital in Baltimore, Maryland. Dr. Putnam spent three years in a Medical Staff Fellowship with the Surgery Branch at the National Cancer Institute in Bethesda, Maryland. In 1986 he completed his General Surgery residency at The University of Rochester School of Medicine and Dentistry in Rochester, New York, as a Senior Assistant Resident and Chief Resident in Surgery. Dr. Putnam received additional specialty training in Thoracic Surgery at The University of Michigan (Ann Arbor) from 1986 to 1988. He joined the staff of The Department of Thoracic & Cardiovascular Surgery at The University of Texas M. D. Anderson Cancer Center in 1988 as an Assistant Surgeon and Assistant Professor of Surgery. In 1994 he was promoted to the position of Associate Surgeon and Associate Professor of Surgery, and in 1995, he assumed the duties as Deputy Chairman of the department. He currently holds joint appointments at The University of Texas Health Science Center and the Harris Country Hospital District (Lyndon Baines Johnson Hospital). During Operation Desert Storm (1990-1991) he assumed Department Head responsibilities in the Department of Cardiothoracic Surgery, Naval Hospital San Diego. Dr. Putnam currently holds the rank of Captain, Medical Corps, United States Naval Reserves.
Dr. Putnam is board certified in Surgery and Thoracic Surgery. He is a Fellow of the American College of Surgeons, a Fellow of the American College of Chest Physicians, and a member of the American Association for Thoracic Surgery, and The Society of Thoracic Surgeons. He has been instrumental in introducing the Video-assisted Thoracoscopy (VATS) techniques into surgery at M. D. Anderson through hands-on training courses. He has also instructed surgeons in several foreign countries on the use of VATS to enhance their surgery efforts. Dr. Putnam has served on various UTMDACC committees, and is currently an active participant on 12 committees. In addition, he is a member of 19 national, international, and state societies and serves on six local, state, national or international committees.
Information
Joe B. Putnam, Jr., M.D.
Professor and Deputy Chairman
Clinical Professor of SurgeryOffices:
Department of Thoracic and Cardiovascular Surgery
The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard, Box 445
Houston, TX 77030-4095
Phone: (713) 792-6934
Fax: (713) 794-4901
E-mail:jputnam
For appointments please call (713) 792-6161 or (800) 392-1611.
Education:
- The University of North Carolina at Chapel Hill, Chapel Hill, NC, A.B. with Honors in Chemistry, 1975
- The University of North Carolina at Chapel Hill, Chapel Hill, NC, M.D., 1979
Hospital Training:
Internship:
- Johns Hopkins Hospital, 1979-80, Surgery
Residencies:
- Resident, The University of Michigan at Ann Arbor, 1986-88, Thoracic Surgery
- Chief Resident, The University of Rochester School of Medicine and Dentistry, 1985-86, Surgery
- Senior Assistant Resident in Surgery, The University of Rochester School of Medicine and Dentistry, 1984-85, Surgery
- Medical Staff Fellow, National Cancer Institute, National Institutes of Health, 1981-84, Surgery Branch
- Junior Assistant Resident, Johns Hopkins Hospital, 1980-81, Surgery
Board Certifications:
- American Board of Thoracic Surgery, Recertification, 1998
- American Board of Thoracic Surgery, 1989
- American Board of Surgery, 1987
Clinical Interests:
Research Interests:
Lung neoplasms, drug delivery system, malignant pleural effusion, data collection
Isolated lung perfusion may safely deliver high levels of drug to the lung and lung tumor, minimize systemic toxicity, and enhance survival. An animal model to test this hypothesis has been developed: isolated single lung perfusion (ISLP) is performed using microsurgical techniques to isolate and perfuse the left lung without systemic perfusion. A model of pulmonary metastases from a syngeneic rodent fibrosarcoma is used to evaluate treatment effects. Biological modifiers may enhance the effects of the perfused drug. A clinical phase I study of ISLP in patients with isolated unresectable pulmonary metastasis from soft tissue sarcomas is under way. In it, the ipsilateral pulmonary artery (PA) and pulmonary vein (PV) are isolated and the lung perfused via the PA over 20 minutes. Effluent drained from the PV is not recirculated. Median Adriamycin (doxorubicin) levels have been found to be higher in the lung tissue than in lung tumors. No intraoperative complications have been noted. Regression or attenuation of ipsilateral pulmonary metastatic growth has been observed in more than half the patients. Late follow-up has revealed a decrease in ventilation and perfusion of the perfused lung compared with the nonperfused lung. Malignant pleural effusions significantly impair function by limiting respiration. Relief of dyspnea has typically required hospitalization and a chest tube for drainage of the effusion. We have evaluated the delivery of doxycycline using a long-term indwelling Silastic pleural catheter versus a chest tube with chemical sclerosis (CT-S) in the management of recurrent malignant pleural effusions. Patients with pleural catheters had significantly fewer hospital days (mean, 1.83) than CT-S patients did (mean, 6.83). None of the patients had significant catheter-related morbidity, and no CT-S patients had symptomatic recurrence of the effusion. We currently use outpatient pleural catheters as standard therapy in our patients with recurrent malignant pleural effusions. A clinical database has been developed for continuous quality improvement and outcomes research. The following prospective clinical variables were previously defined and are collected on all patients at various points in each patient's care: preoperative data and comorbidities, operating room data, postoperative events, and follow-up information. Clinical and pathologic staging is also done for all patients. Clinical variables, process variables, and costs of care are being evaluated.
